Adenosine A2A receptor antagonists act at the hyperoxic phase to confer protection against retinopathy

Abstract

As ROP being a biphasic disease, our identification of the hyperoxic phase as the effective window, together with selective and robust protection against pathological (but not physiological) angiogenesis, elevates A_2AR antagonists as a novel therapeutic strategy for ROP treatment.